GO
Loading...

Gilead Sciences Inc

More

  • Midday Glance: Biotechnology companies Thursday, 9 Apr 2015 | 1:41 PM ET

    Amgen Inc. rose$. 85 or. 5 percent, to $161.18. Biogen Idec fell $1.15 or. 3 percent, to $424.21. Celgene Corp. fell$. 16 or. 1 percent, to $114.99.

  • Early Glance: Biotechnology companies Thursday, 9 Apr 2015 | 10:26 AM ET

    Amgen Inc. rose$. 35 or. 2 percent, to $160.68. Biogen Idec rose $2.58 or. 6 percent, to $427.94. Celgene Corp. rose$. 05 or percent, to $115.20.

  • Final Glance: Biotechnology companies Wednesday, 8 Apr 2015 | 6:42 PM ET

    Amgen Inc. rose $3.05 or 1.9 percent, to $160.33. Biogen Idec rose $7.27 or 1.7 percent, to $425.36. Celgene Corp. rose $2.43 or 2.2 percent, to $115.15.

  • Midday Glance: Biotechnology companies Wednesday, 8 Apr 2015 | 2:03 PM ET

    Amgen Inc. rose $2.41 or 1.5 percent, to $159.69. Biogen Idec rose $4.89 or 1.2 percent, to $422.98. Celgene Corp. rose $2.55 or 2.3 percent, to $115.27.

  • Early Glance: Biotechnology companies Wednesday, 8 Apr 2015 | 12:57 PM ET

    Amgen Inc. rose $1.88 or 1.2 percent, to $159.16. Biogen Idec rose $8.05 or 1.9 percent, to $426.14. Celgene Corp. rose $1.55 or 1.4 percent, to $114.27.

  • Final Glance: Biotechnology companies Tuesday, 7 Apr 2015 | 6:15 PM ET

    Amgen Inc. rose $2.00 or 1.3 percent, to $157.28. Biogen Idec rose $4.67 or 1.1 percent, to $418.09. Celgene Corp. fell$. 25 or. 2 percent, to $112.72.

  • Midday Glance: Biotechnology companies Tuesday, 7 Apr 2015 | 2:30 PM ET

    Amgen Inc. rose $3.47 or 2.2 percent, to $158.75. Biogen Idec rose $9.78 or 2.4 percent, to $423.20. Celgene Corp. rose$. 86 or. 8 percent, to $113.83.

  • Early Glance: Biotechnology companies Tuesday, 7 Apr 2015 | 11:04 AM ET

    Amgen Inc. rose $2.11 or 1.4 percent, to $157.39. Biogen Idec rose $8.04 or 1.9 percent, to $421.46. Celgene Corp. rose $1.78 or 1.6 percent, to $114.75.

  • Final Glance: Biotechnology companies Monday, 6 Apr 2015 | 6:20 PM ET

    Amgen Inc. fell$. 60 or. 4 percent, to $155.28. Biogen Idec rose$. 98 or. 2 percent, to $413.42. Celgene Corp. fell $1.34 or 1.2 percent, to $112.97.

  • Midday Glance: Biotechnology companies Monday, 6 Apr 2015 | 1:31 PM ET

    Amgen Inc. rose $1.15 or. 7 percent, to $157.03. Biogen Idec rose $5.71 or 1.4 percent, to $418.15. Celgene Corp. rose$. 10 or. 1 percent, to $114.41.

  • Early Glance: Biotechnology companies Monday, 6 Apr 2015 | 11:23 AM ET

    Amgen Inc. fell $1.04 or. 7 percent, to $154.84. Biogen Idec fell $1.40 or. 3 percent, to $411.05. Celgene Corp. fell$. 75 or. 7 percent, to $113.56.

  • Earnings outlook grows bleak. What to buy Wednesday, 1 Apr 2015 | 12:16 PM ET
    A file photo of a FedEx truck

    The upcoming earnings season is forging a bleak outlook for investors. CNBC Pro highlights some of the top picks on the street.

  • Cramer: The best places for you to put new money Monday, 30 Mar 2015 | 6:55 PM ET
    A Cofor worker wearing a safety hard hat moves drilling pipes near to a rig at the geothermal energy drilling site operated by Semhach SA in Villejuif, France.

    Jim Cramer reveals the top places to invest new money on the stock market.

  • March 26- French drugmaker Genfit SA said on Thursday it will begin a late stage trial later this year of its lead treatment for a liver-destroying condition, saying it failed a midstage trial in part due to its inclusion of many patients with a mild form of the disease. When adjusting for those factors, the results were "quite robust for NASH," Dean Hum, the company's...

  • Biotech woes: Deja vu all over again Thursday, 26 Mar 2015 | 12:59 PM ET
    Biotech

    For biotech watchers, it's deja vu all over again. Through Wednesday, the Nasdaq Biotechnology Index dropped 6.9 percent since the close March 20.

  • March 26- Conatus Pharmaceuticals Inc said its experimental lead drug was more effective than a placebo in a mid-stage study in patients with a form of fatty liver disease. Several drugmakers, including Gilead Sciences Inc, Intercept Pharmaceuticals Inc and France's Genfit SA, are in the race to develop treatments. Conatus estimates that about 2 million...

  • Conatus Pharma's liver drug succeeds in mid-stage study Thursday, 26 Mar 2015 | 7:02 AM ET

    March 26- Conatus Pharmaceuticals Inc said its experimental lead drug was more effective than a placebo in a mid-stage study in patients with a form of fatty liver disease. Several drugmakers, including Gilead Sciences Inc, Intercept Pharmaceuticals Inc and France's Genfit SA, are in the race to develop treatments. Conatus estimates that about 2 million...

  • BOSTON, March 25- CEOs at large U.S. companies collectively realized at least $6 billion more in compensation than initially estimated in annual disclosures in the five years after the financial crisis first hit, according to a Reuters analysis. About 300 CEOs who served throughout the 2009-2013 period at S&P 500 companies together realized about $22 billion...

  • Biotech done? And an under-the-radar top stock Tuesday, 24 Mar 2015 | 12:27 PM ET
    Harvoni

    In his latest "New Ideas" column for CNBC Pro, Brian Sullivan discusses the dollar-oil link, a biotech bubble and the hottest stock of the year.

  • *Dollar dips but oversupply worry weighs on oil. NEW YORK, March 23- U.S. stocks were little changed on Monday on the heels of a rally in the prior week, as investors weighed fluctuations in the dollar and its impact on other markets, including crude prices. The Nasdaq was less than 0.5 percent of a closing record set on March 10, 2000.